September 10, 2018 10:08 AM EDTUpdated 10:20 AM
News Briefing

NHS re­fus­es to cov­er Ocre­vus for pri­ma­ry pro­gres­sive MS; OxStem taps vet­er­an drug hunter Georg Ter­stap­pen as CSO

ENDPOINTS

→ UK drug price watch­dog NICE is not rec­om­mend­ing NHS cov­er­age of Roche’s Ocre­vus for pri­ma­ry pro­gres­sive mul­ti­ple scle­ro­sis. The de­ci­sion im­me­di­ate­ly trig­gered an …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ver­tex gets 'van­za triple' ap­proval and Trikaf­ta ex­pan­sion — with boxed warn­ings

No­vo Nordisk’s once-dai­ly he­mo­phil­ia drug Al­he­mo ap­proved in US

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

GSK's Ze­ju­la-Jem­per­li com­bo in ovar­i­an can­cer hits pri­ma­ry end­point, miss­es on over­all sur­vival

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

A service from the Financial Times